| Style | Citing Format |
|---|---|
| MLA | Darvishian M, et al.. "Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply." The Lancet Infectious Diseases, vol. 21, no. 5, 2021, pp. 604-605. |
| APA | Darvishian M, Sharafkhah M, Poustchi H, Malekzadeh R (2021). Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply. The Lancet Infectious Diseases, 21(5), 604-605. |
| Chicago | Darvishian M, Sharafkhah M, Poustchi H, Malekzadeh R. "Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply." The Lancet Infectious Diseases 21, no. 5 (2021): 604-605. |
| Harvard | Darvishian M et al. (2021) 'Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply', The Lancet Infectious Diseases, 21(5), pp. 604-605. |
| Vancouver | Darvishian M, Sharafkhah M, Poustchi H, Malekzadeh R. Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply. The Lancet Infectious Diseases. 2021;21(5):604-605. |
| BibTex | @article{ author = {Darvishian M and Sharafkhah M and Poustchi H and Malekzadeh R}, title = {Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply}, journal = {The Lancet Infectious Diseases}, volume = {21}, number = {5}, pages = {604-605}, year = {2021} } |
| RIS | TY - JOUR AU - Darvishian M AU - Sharafkhah M AU - Poustchi H AU - Malekzadeh R TI - Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply JO - The Lancet Infectious Diseases VL - 21 IS - 5 SP - 604 EP - 605 PY - 2021 ER - |